Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Stoke Therapeutics to Present at Upcoming Investor Conferences in August

Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that members of management will present at three upcoming investor conferences in August:

2020 Wedbush PacGrow Healthcare Virtual Conference
Tuesday, August 11, 2020
Time: 11:30 a.m. ET

BTIG Virtual Biotechnology Conference
Tuesday, August 11, 2020
Time: 2:00 p.m. ET

Canaccord Genuity 40th Annual Growth Conference
Wednesday, August 12, 2020
Time: 2:30 p.m. ET

A live audio webcast of each presentation will be available on the Investors & Media section of Stoke's website at https://investor.stoketherapeutics.com/. A replay of the webcasts will be available for 30 days following the presentations.

About Stoke Therapeutics

Stoke Therapeutics, Inc. (Nasdaq: STOK), is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. The company's lead investigational new medicine is STK-001, a proprietary antisense oligonucleotide (ASO) that has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome, a severe and progressive genetic epilepsy. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the company on Twitter at @StokeTx.

These press releases may also interest you

at 12:04
Reference is made to the stock exchange announcements on 23 September 2020 where Nordic Nanovector ASA (the "Company") announced that the Company had carried out a successful private placement raising gross proceeds of approximately NOK 231 million...

at 12:03
Adrenaline, Inc., the leader in the U.S. adventure experience marketplace since its launch in 2012, has announced that its founders have appointed Brendan Nugent as chief executive officer as part of the company's strategic plan for growth. ...

at 12:00
According to market research report on "Higher Education Market by Component (Solutions and Services), Solution (Student Information Management System, Content Collaboration, Data Security and Compliance, Campus Management), Deployment Type,...

at 12:00
Harte Hanks, a global, behavior-driven customer experience (CX) company, announced today that it has named Drew Rayman to the newly created role of Managing Director, eCommerce. Rayman will launch, develop and oversee the new Harte Hanks DTC &...

at 11:50
The "Funeral Home Software Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Deployment Type and Organization Size" report has been added to ResearchAndMarkets.com's offering. According to this report the market was valued US$ 277.91...

at 11:49
Einvestment's fund has allocated ?22M to the AI and Robotics sector. The Sustainable Growth portfolio that includes the investment has increased significantly over the last two years. Since its inception, the return has already exceeded 100%....

News published on 4 august 2020 at 07:35 and distributed by: